Fig. 1: The 2-year probabilities of clinical outcomes according to MRD status for patients with adverse-risk AML receiving allo-HSCT. | Blood Cancer Journal

Fig. 1: The 2-year probabilities of clinical outcomes according to MRD status for patients with adverse-risk AML receiving allo-HSCT.

From: MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study

Fig. 1

(A) relapse, (B) LFS and (C) OS after the first consolidation chemotherapy; the effect of MRDcon1 level on (D) relapse and (E) death; (F) relapse, (G) LFS and (H) OS after the second consolidation chemotherapy; the effect of MRDcon2 level on (I) relapse and (J) death; (K) relapse, (L) LFS and (M) OS before transplantation; the effect of MRDbft level on (N) relapse and (O) death.

Back to article page